JNJ Volume Alert - JNJ 108.21 Johnson & Johnson $JNJ Hit a high of 108.20 Currently 11:15 Last price 108.21 +0.01 +0.01% With a day low of 107.20 and a current volume of 2,560,275.
JNJ Johnson & Johnson Recent Headline News
Midday Glance: Pharmaceuticals companies
AP - 2 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.59 (+0.39), BAX: 70.53 (-0.08), PFE: 30.23 (+0.31), BMY: 58.56 (+0.24)
Midday Glance: Medical Devices companies
AP - 2 mins ago
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 109.93 (+1.74), JNJ: 108.59 (+0.39), MDT: 68.43 (+0.33), BAX: 70.53 (-0.08)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - 1 hr 42 mins ago
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.63 (-0.03), CRIS: 1.35 (+0.05), IMMU: 3.66 (+0.05), PCYC: 133.24 (-0.25), ONCY: 0.81 (+0.11), PFE: 30.23 (+0.31), LLY: 67.87 (+1.27), BMY: 58.56 (+0.24), GSK: 45.19 (+0.28), JNJ: 108.59 (+0.39), SNTA: 3.12 (-0.02), NVS: 92.39 (+0.63), XLRN: 31.85 (+1.66), ARRY: 3.90 (+0.02), CELGZ: 3.17 (-0.07), EXEL: 1.76 (+0.02)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 2 hrs 16 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.59 (+0.39), GILD: 107.25 (+0.80), ACHN: 12.38 (+2.27), MRK: 58.96 (-0.38), ABBV: 63.47 (+1.97), BMY: 58.56 (+0.24)
Johnson & Johnson (JNJ) Crosses Pivot Point Support at $107.74
Comtex SmarTrend(R) - 2 hrs 32 mins ago
Shares of Johnson & Johnson (NYSE:JNJ) opened today below their pivot of $108.38 and have already reached the first level of support at $107.74. Should the shares continue to fall, the support pivots of $107.27 and $106.16 will be of interest.
JNJ: 108.59 (+0.39)
4 Stocks to Look at via Ebola Crisis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 47 mins ago
Here are four stocks poised to benefit from bringing treatment for the dreaded virus Ebola.
MMM: 157.31 (+0.76), BCRX: 10.76 (+0.30), TK: 54.45 (-0.45), CCL: 40.26 (-0.14), DAL: 43.12 (+0.43), KMB: 113.51 (+0.27), DIS: 89.35 (-0.65), JBLU: 12.93 (+0.37), GSK: 45.19 (+0.28), MAR: 76.23 (+0.73), UAL: 54.88 (+0.70), LUV: 38.79 (+0.55), INO: 10.84 (-0.39), JNJ: 108.59 (+0.39), RCL: 67.51 (+0.31), APT: 3.23 (-0.03)
Early Glance: Pharmaceuticals companies
AP - Mon Nov 10, 9:28AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.59 (+0.39), BAX: 70.53 (-0.08), PFE: 30.23 (+0.31), BMY: 58.56 (+0.24)
Early Glance: Medical Devices companies
AP - Mon Nov 10, 9:28AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 109.93 (+1.74), JNJ: 108.59 (+0.39), MDT: 68.43 (+0.33), BAX: 70.53 (-0.08)
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 109.26 (-3.51), ABMD: 32.88 (+0.75), JNJ: 108.59 (+0.39), AMGN: 162.19 (+1.94), EXAS: 22.47 (-0.35), ARAY: 6.84 (-0.01), HOLX: 26.40 (+0.19), PBYI: 238.88 (+1.99)
3 Stocks for the Next 100 Years
Motley Fool Staff - Motley Fool - Mon Nov 10, 7:49AM CST
The ability to identify great companies that can withstand and thrive for generations is critical to achieving long-haul investment success; just ask Warren Buffett. After all, his investment in Coca-Cola is the gold standard for that type of...
KO: 42.38 (+0.06), JNJ: 108.59 (+0.39), AXP: 92.23 (-0.03), MTB: 124.14 (-0.40)
Johnson & Johnson acquires Alios BioPharma for USD1.75bn
M2 - Mon Nov 10, 7:46AM CST
Healthcare company Johnson & Johnson (NYSE:JNJ) stated on Friday that it has closed the acquisition of Alios BioPharma for a total purchase price of about USD1.75bn in cash.
JNJ: 108.59 (+0.39)
HackerAgency Names New Director of Strategic Planning; Adds Senior Client Leadership
PR Newswire - Mon Nov 10, 7:35AM CST
Global digital/direct marketing agency HackerAgency announced today that Jay Levinger has been named Director of Strategic Planning and that Chris Bennett has joined the agency as Account Director, Acquisition and Retention.
JNJ: 108.59 (+0.39)
Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About Afib(SM)
Business Wire - Mon Nov 10, 7:00AM CST
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, has partnered with advocacy organization StopAfib.org to encourage Americans to Get SMART About Afib(SM). The initiative sets out to raise awareness of atrial fibrillation, or Afib, and available treatment options to better support the estimated three million people in the U.S. who are living with the condition. People can study up on Afib through an interactive website experience by logging on to www.GetSMARTAboutAfib.com.(1)
JNJ: 108.59 (+0.39)
The Next Chapter in Dendron's Troubled History: Chapter 11 Bankruptcy
at The Street - Mon Nov 10, 6:12AM CST
A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.
MDVN: 109.26 (-3.51), JNJ: 108.59 (+0.39), DNDN: 0.23 (-0.71)
MLPs: 3 Reasons Dividend Investors Should Love Them
Adam Galas, The Motley Fool - Motley Fool - Sun Nov 09, 2:09PM CST
The power of dividend growth investing to generate long-term wealth and help people meet their financial dreams, such as a prosperous and sustainable retirement, has been well documented . Many investors are aware of dividend aristocrats;...
KMI: 38.59 (-0.16), EPB: 40.80 (-0.11), JNJ: 108.59 (+0.39), KMR: 95.29 (-0.29), XOM: 96.39 (-0.20), WMT: 80.01 (+1.24), KMP: 94.71 (-0.02)
5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 109.26 (-3.51), JNJ: 108.59 (+0.39), BIIB: 325.92 (+5.17), PTLA: 27.38 (-0.01), GILD: 107.25 (+0.80), CELG: 107.65 (+1.20)
Stocks that could benefit from a GOP-led Congress
By KEN SWEET - AP - Sat Nov 08, 8:07AM CST
NEW YORK (AP) — Lower taxes for medical device makers. Lighter regulations for coal. If the new Republican-led Congress manages to push through these policy changes it could lift stocks in the health and energy industries, market strategists say.
JNJ: 108.59 (+0.39), MDT: 68.43 (+0.33), ZION: 29.63 (-0.04)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 195.28 (-0.72), JNJ: 108.59 (+0.39), GILD: 107.25 (+0.80), ABBV: 63.47 (+1.97)
New President and New Offices Signal New Era for New Jersey-based BNO
PR Newswire - Fri Nov 07, 5:36PM CST
Baldwin & Obenauf, Inc. (BNO), an award-winning creative agency with a roster of clients that includes Johnson & Johnson, MasterCard, and BASF, has named a new president and moved its headquarters to Somerville, NJ.
JNJ: 108.59 (+0.39)
Final Glance: Pharmaceuticals companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.59 (+0.39), BAX: 70.53 (-0.08), PFE: 30.23 (+0.31), BMY: 58.56 (+0.24)
JNJ Johnson & Johnson Recent Headline News
Midday Glance: Pharmaceuticals companies
AP - 2 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.59 (+0.39), BAX: 70.53 (-0.08), PFE: 30.23 (+0.31), BMY: 58.56 (+0.24)
Midday Glance: Medical Devices companies
AP - 2 mins ago
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 109.93 (+1.74), JNJ: 108.59 (+0.39), MDT: 68.43 (+0.33), BAX: 70.53 (-0.08)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - 1 hr 42 mins ago
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.63 (-0.03), CRIS: 1.35 (+0.05), IMMU: 3.66 (+0.05), PCYC: 133.24 (-0.25), ONCY: 0.81 (+0.11), PFE: 30.23 (+0.31), LLY: 67.87 (+1.27), BMY: 58.56 (+0.24), GSK: 45.19 (+0.28), JNJ: 108.59 (+0.39), SNTA: 3.12 (-0.02), NVS: 92.39 (+0.63), XLRN: 31.85 (+1.66), ARRY: 3.90 (+0.02), CELGZ: 3.17 (-0.07), EXEL: 1.76 (+0.02)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 2 hrs 16 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.59 (+0.39), GILD: 107.25 (+0.80), ACHN: 12.38 (+2.27), MRK: 58.96 (-0.38), ABBV: 63.47 (+1.97), BMY: 58.56 (+0.24)
Johnson & Johnson (JNJ) Crosses Pivot Point Support at $107.74
Comtex SmarTrend(R) - 2 hrs 32 mins ago
Shares of Johnson & Johnson (NYSE:JNJ) opened today below their pivot of $108.38 and have already reached the first level of support at $107.74. Should the shares continue to fall, the support pivots of $107.27 and $106.16 will be of interest.
JNJ: 108.59 (+0.39)
4 Stocks to Look at via Ebola Crisis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 47 mins ago
Here are four stocks poised to benefit from bringing treatment for the dreaded virus Ebola.
MMM: 157.31 (+0.76), BCRX: 10.76 (+0.30), TK: 54.45 (-0.45), CCL: 40.26 (-0.14), DAL: 43.12 (+0.43), KMB: 113.51 (+0.27), DIS: 89.35 (-0.65), JBLU: 12.93 (+0.37), GSK: 45.19 (+0.28), MAR: 76.23 (+0.73), UAL: 54.88 (+0.70), LUV: 38.79 (+0.55), INO: 10.84 (-0.39), JNJ: 108.59 (+0.39), RCL: 67.51 (+0.31), APT: 3.23 (-0.03)
Early Glance: Pharmaceuticals companies
AP - Mon Nov 10, 9:28AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.59 (+0.39), BAX: 70.53 (-0.08), PFE: 30.23 (+0.31), BMY: 58.56 (+0.24)
Early Glance: Medical Devices companies
AP - Mon Nov 10, 9:28AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 109.93 (+1.74), JNJ: 108.59 (+0.39), MDT: 68.43 (+0.33), BAX: 70.53 (-0.08)
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 109.26 (-3.51), ABMD: 32.88 (+0.75), JNJ: 108.59 (+0.39), AMGN: 162.19 (+1.94), EXAS: 22.47 (-0.35), ARAY: 6.84 (-0.01), HOLX: 26.40 (+0.19), PBYI: 238.88 (+1.99)
3 Stocks for the Next 100 Years
Motley Fool Staff - Motley Fool - Mon Nov 10, 7:49AM CST
The ability to identify great companies that can withstand and thrive for generations is critical to achieving long-haul investment success; just ask Warren Buffett. After all, his investment in Coca-Cola is the gold standard for that type of...
KO: 42.38 (+0.06), JNJ: 108.59 (+0.39), AXP: 92.23 (-0.03), MTB: 124.14 (-0.40)
Johnson & Johnson acquires Alios BioPharma for USD1.75bn
M2 - Mon Nov 10, 7:46AM CST
Healthcare company Johnson & Johnson (NYSE:JNJ) stated on Friday that it has closed the acquisition of Alios BioPharma for a total purchase price of about USD1.75bn in cash.
JNJ: 108.59 (+0.39)
HackerAgency Names New Director of Strategic Planning; Adds Senior Client Leadership
PR Newswire - Mon Nov 10, 7:35AM CST
Global digital/direct marketing agency HackerAgency announced today that Jay Levinger has been named Director of Strategic Planning and that Chris Bennett has joined the agency as Account Director, Acquisition and Retention.
JNJ: 108.59 (+0.39)
Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About Afib(SM)
Business Wire - Mon Nov 10, 7:00AM CST
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, has partnered with advocacy organization StopAfib.org to encourage Americans to Get SMART About Afib(SM). The initiative sets out to raise awareness of atrial fibrillation, or Afib, and available treatment options to better support the estimated three million people in the U.S. who are living with the condition. People can study up on Afib through an interactive website experience by logging on to www.GetSMARTAboutAfib.com.(1)
JNJ: 108.59 (+0.39)
The Next Chapter in Dendron's Troubled History: Chapter 11 Bankruptcy
at The Street - Mon Nov 10, 6:12AM CST
A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.
MDVN: 109.26 (-3.51), JNJ: 108.59 (+0.39), DNDN: 0.23 (-0.71)
MLPs: 3 Reasons Dividend Investors Should Love Them
Adam Galas, The Motley Fool - Motley Fool - Sun Nov 09, 2:09PM CST
The power of dividend growth investing to generate long-term wealth and help people meet their financial dreams, such as a prosperous and sustainable retirement, has been well documented . Many investors are aware of dividend aristocrats;...
KMI: 38.59 (-0.16), EPB: 40.80 (-0.11), JNJ: 108.59 (+0.39), KMR: 95.29 (-0.29), XOM: 96.39 (-0.20), WMT: 80.01 (+1.24), KMP: 94.71 (-0.02)
5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 109.26 (-3.51), JNJ: 108.59 (+0.39), BIIB: 325.92 (+5.17), PTLA: 27.38 (-0.01), GILD: 107.25 (+0.80), CELG: 107.65 (+1.20)
Stocks that could benefit from a GOP-led Congress
By KEN SWEET - AP - Sat Nov 08, 8:07AM CST
NEW YORK (AP) — Lower taxes for medical device makers. Lighter regulations for coal. If the new Republican-led Congress manages to push through these policy changes it could lift stocks in the health and energy industries, market strategists say.
JNJ: 108.59 (+0.39), MDT: 68.43 (+0.33), ZION: 29.63 (-0.04)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 195.28 (-0.72), JNJ: 108.59 (+0.39), GILD: 107.25 (+0.80), ABBV: 63.47 (+1.97)
New President and New Offices Signal New Era for New Jersey-based BNO
PR Newswire - Fri Nov 07, 5:36PM CST
Baldwin & Obenauf, Inc. (BNO), an award-winning creative agency with a roster of clients that includes Johnson & Johnson, MasterCard, and BASF, has named a new president and moved its headquarters to Somerville, NJ.
JNJ: 108.59 (+0.39)
Final Glance: Pharmaceuticals companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.59 (+0.39), BAX: 70.53 (-0.08), PFE: 30.23 (+0.31), BMY: 58.56 (+0.24)
